SCHEMBL14680413

SCHEMBL14680413

COc1cccc(OCc2nnc(SCc3ccccc3)n2C)c1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.70
TDP1 Q9NUW8 1/20 0.70
PKM P14618 1/20 0.62
TSHR P16473 2/20 0.58
MEN1 O00255 1/20 0.58
KMT2A Q03164 1/20 0.58
SIRT2 Q8IXJ6 3/20 0.57
CYP2C9 P11712 1/20 0.54
CYP2C19 P33261 1/20 0.54
RECQL P46063 1/20 0.54
MAPK1 P28482 2/20 0.53
GAA P10253 2/20 0.53
HSD17B10 Q99714 1/20 0.53
MAOB P27338 1/20 0.53
NPC1 O15118 1/20 0.53
SMN1; SMN2 Q16637 2/20 0.53
NPSR1 Q6W5P4 1/20 0.53
USP2 O75604 1/20 0.53
HPGD P15428 1/20 0.53
POLB P06746 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4209355 0.85 NPC1 (0.72) ALDH1A1TDP1PKMTSHRSIRT2
SCHEMBL6405832 0.83 ALDH1A1 (1.00) ALDH1A1TDP1PKMTSHRMEN1
SCHEMBL6403245 0.74 TSHR (0.82) ALDH1A1PKMTSHRMEN1KMT2A
SCHEMBL19274604 0.73 CYP3A4 (0.60) ALDH1A1TSHRMEN1KMT2ACYP2C9
SCHEMBL6408137 0.73 SIRT2 (0.69) TDP1PKMTSHRMEN1KMT2A
SCHEMBL16409978 0.73 SIRT2 (1.00) ALDH1A1TSHRMEN1KMT2ASIRT2
SCHEMBL791569 0.72 MAOB (1.00) MAOB
SCHEMBL4206785 0.72 RAB9A (0.75) ALDH1A1TSHRMEN1KMT2ACYP2C19
SCHEMBL4214358 0.70 LMNA (0.71) ALDH1A1TDP1TSHRMEN1KMT2A
SCHEMBL5968206 0.70 ALDH1A1 (0.54) ALDH1A1TDP1PKMTSHRMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10000511-B2 Small molecules for the modulation of MCL-1 and methods of modulating cell death, cell division, cell differentiation and methods of treating disorders DANA-FARBER CANCER INSTITUTE, INC. (US) 2018-06-19 US disclosed
US-20170281649-A1 COMPOUNDS AND THERAPEUTIC USES UNITY BIOTECHNOLOGY, INC. 2017-10-05 US disclosed
US-20150315211-A1 SMALL MOLECULES FOR THE MODULATION OF MCL-1 AND METHODS OF MODULATING CELL DEATH, CELL DIVISION, CELL DIFFERENTIATION AND METHODS OF TREATING DISORDERS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2015-11-05 US disclosed
US-20130035304-A1 SMALL MOLECULES FOR THE MODULATION OF MCL-1 AND METHODS OF MODULATING CELL DEATH, CELL DIVISION, CELL DIFFERENTIATION AND METHODS OF TREATING DISORDERS NATIONAL INSTITUTES OF HEALTH-DIRECTOR DEITR 2013-02-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170281649-A1 COMPOUNDS AND THERAPEUTIC USES TP53, NQO1, SHMT2 ALDH1A1 545/4885TDP1 77/4885PKM 1966/4885
US-20130035304-A1 SMALL MOLECULES FOR THE MODULATION OF MCL-1 AND METHODS OF MODULATING CELL DEATH, CELL DIVISION, CELL DIFFERENTIATION AND METHODS OF TREATING DISORDERS MCL1, BCL2, BCL2L1 ALDH1A1 2862/4885TDP1 2063/4885PKM 2938/4885
US-10000511-B2 Small molecules for the modulation of MCL-1 and methods of modulating cell death, cell division, cell differentiation and methods of treating disorders MCL1, BCL2, BCL2L1 ALDH1A1 2862/4885TDP1 2063/4885PKM 2938/4885
US-20150315211-A1 SMALL MOLECULES FOR THE MODULATION OF MCL-1 AND METHODS OF MODULATING CELL DEATH, CELL DIVISION, CELL DIFFERENTIATION AND METHODS OF TREATING DISORDERS MCL1, BCL2, BCL2L1 ALDH1A1 2862/4885TDP1 2063/4885PKM 2938/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.